FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 729 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... March 15, 2022 Patient Guide on Cancer Pain Management Now Available Also in French December 16, 2025 Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 Coronavirus reports – Part 8: “Going into hospital during this time... December 18, 2020 Load more HOT NEWS Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now... ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ Median Survival Times for Two Forms of Advanced Breast Cancer Have...
